Literature DB >> 24838908

Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries.

Jørgen T Lauridsen1, Jonas Lønborg, Jens Gundgaard, Henrik Holm Jensen.   

Abstract

INTRODUCTION: The negative impact of hypoglycaemic events on health-related quality of life (HRQoL) may be evaluated by attaching published disutilities to these events. It is suggested that the marginal negative impact of individual hypoglycaemic events on HRQoL may decrease as the overall frequency increases.
METHODS: Using disutility values from a large-scale (>8,000 respondents), time trade-off (TTO) study, nonlinear regression curves were fitted to the total disutility of different frequencies of non-severe daytime and nocturnal hypoglycaemic events. Nonparametric bootstrapping was applied to characterise the uncertainty of the marginal disutility.
RESULTS: Power function regression curves were estimated at U d = 0.0141x (0.3393) and U d = 0.0221x (0.3277). An increase from 0 to 1 hypoglycaemic event per year produced a utility decrease of 0.0141 and 0.0221 for non-severe daytime and nocturnal events, respectively. An increase from 25 to 26 events per year produced a marginal impact of 0.0006 and 0.0008 for non-severe daytime and nocturnal events, respectively. DISCUSSION: These data concur with the noted phenomenon of "first being worst" as regards hypoglycaemic events. This finding may reflect a coping mechanism on the part of patients, a maximum limit for trading off remaining lifetime or the nature of the study.
CONCLUSION: Applying nonlinear functions to the TTO data might improve the precision of the measured impact of hypoglycaemic events.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24838908     DOI: 10.1007/s11136-014-0712-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  18 in total

1.  Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

Authors:  Craig J Currie; Christopher Ll Morgan; Chris D Poole; Peter Sharplin; Morten Lammert; Phil McEwan
Journal:  Curr Med Res Opin       Date:  2006-08       Impact factor: 2.580

Review 2.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

Authors: 
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

3.  Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.

Authors:  L A Donnelly; A D Morris; B M Frier; J D Ellis; P T Donnan; R Durrant; M M Band; G Reekie; G P Leese
Journal:  Diabet Med       Date:  2005-06       Impact factor: 4.359

Review 4.  Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention.

Authors:  Kate V Allen; Brian M Frier
Journal:  Endocr Pract       Date:  2003 Nov-Dec       Impact factor: 3.443

5.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

6.  Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Authors:  Philip Clarke; Alastair Gray; Rury Holman
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583

7.  Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study.

Authors:  Elizabeth Marrett; Larry Radican; Michael J Davies; Qiaoyi Zhang
Journal:  BMC Res Notes       Date:  2011-07-21

8.  Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.

Authors:  Marc Evans; Kamlesh Khunti; Muhammad Mamdani; Claus B Galbo-Jørgensen; Jens Gundgaard; Mette Bøgelund; Stewart Harris
Journal:  Health Qual Life Outcomes       Date:  2013-06-03       Impact factor: 3.186

9.  Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom.

Authors:  Adrian R Levy; Torsten Lu Christensen; Jeffrey A Johnson
Journal:  Health Qual Life Outcomes       Date:  2008-09-29       Impact factor: 3.186

10.  Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.

Authors:  Stewart B Harris; Kamlesh Khunti; Mona Landin-Olsson; Claus B Galbo-Jørgensen; Mette Bøgelund; Barrie Chubb; Jens Gundgaard; Marc Evans
Journal:  Patient Prefer Adherence       Date:  2013-09-16       Impact factor: 2.711

View more
  13 in total

1.  The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.

Authors:  Josep Franch-Nadal; Samuel J P Malkin; Barnaby Hunt; Virginia Martín; María Gallego Estébanez; Josep Vidal
Journal:  Adv Ther       Date:  2022-05-12       Impact factor: 4.070

2.  Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.

Authors:  Gabriela Vega-Hernandez; Radek Wojcik; Max Schlueter
Journal:  Diabetes Ther       Date:  2017-03-27       Impact factor: 2.945

3.  The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus.

Authors:  Phil McEwan; Hayley Bennett; Jonathan Fellows; Jennifer Priaulx; Klas Bergenheim
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

4.  Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.

Authors:  Richard F Pollock; Barrie Chubb; William J Valentine; Simon Heller
Journal:  Diabetes Metab Syndr Obes       Date:  2018-05-16       Impact factor: 3.168

5.  Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.

Authors:  David Russell-Jones; Simon R Heller; Sarah Buchs; Anna Sandberg; William J Valentine; Barnaby Hunt
Journal:  Diabetes Obes Metab       Date:  2017-07-25       Impact factor: 6.577

6.  Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.

Authors:  Samuel J P Malkin; Monika Russel-Szymczyk; Girtel Liidemann; Vallo Volke; Barnaby Hunt
Journal:  Diabetes Ther       Date:  2018-12-07       Impact factor: 2.945

7.  Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.

Authors:  Johannes Pöhlmann; Roberta Montagnoli; Giusi Lastoria; Witesh Parekh; Marie Markert; Barnaby Hunt
Journal:  Clinicoecon Outcomes Res       Date:  2019-10-07

Review 8.  The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden.

Authors:  S Pinar Bilir; Richard Hellmund; Elizabeth Wehler; Huimin Li; Julie Munakata; Mark Lamotte
Journal:  Eur Endocrinol       Date:  2018-09-10

Review 9.  Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden.

Authors:  S Pinar Bilir; Richard Hellmund; Beth Wehler; Huimin Li; Julie Munakata; Mark Lamotte
Journal:  Eur Endocrinol       Date:  2018-09-10

10.  Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.

Authors:  Johannes Pöhlmann; Monika Russel-Szymczyk; Pavel Holík; Karel Rychna; Barnaby Hunt
Journal:  Diabetes Ther       Date:  2019-01-31       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.